Characterization of Nonpathogenic, Live, Viral Vaccine Vectors Inducing Potent Cellular Immune Responses

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Virology

• Publication date

  2004-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.78.17.9317-9324.2004PMID 15308726PMCID PMC506945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunopathogenesis and immunotherapy in AIDS virus infections

  2003cited by this paper
• Intranasal Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing Cottontail Rabbit Papillomavirus L1 Protein Provides Complete Protection against Papillomavirus-Induced Disease

  2002cited by this paper
• Progression of Armed CTL from Draining Lymph Node to Spleen Shortly After Localized Infection with Herpes Simplex Virus 11

  2002cited by this paper
• High-Level Primary CD8+ T-Cell Response to Human Immunodeficiency Virus Type 1 Gag and Env Generated by Vaccination with Recombinant Vesicular Stomatitis Viruses

  2002cited by this paper
• Replication-Competent or Attenuated, Nonpropagating Vesicular Stomatitis Viruses Expressing Respiratory Syncytial Virus (RSV) Antigens Protect Mice against RSV Challenge

  2001cited by this paper
• An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

  2001cited by this paper
• Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.

  2000cited by this paper
• Successful Vaccine-Induced Seroconversion by Single-Dose Immunization in the Presence of Measles Virus-Specific Maternal Antibodies

  2000cited by this paper
• Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Attenuated Vesicular Stomatitis Viruses as Vaccine Vectors

  1999cited by this paper
• Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

  1999cited by this paper
• Requirement for a non‐specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus

  1998cited by this paper
• Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing an Influenza Virus Hemagglutinin Provides Complete Protection from Influenza Virus Challenge

  1998cited by this paper
• Requirement for CD44 in activated T cell extravasation into an inflammatory site.

  1997cited by this paper
• Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins

  1997cited by this paper
• Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein

  1996cited by this paper
• The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus

  1996cited by this paper
• Lymphocytic Choriomeningitis Virus Infection is Associated with Long‐Standing Perturbation of LFA‐1 Expression on CD8+ T Cells

  1995cited by this paper
• Recombinant vesicular stomatitis viruses from DNA.

  1995cited by this paper
• Changes in cell adhesion molecule expression on T cells associated with systemic virus infection.

  1994cited by this paper
• Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

  1994cited by this paper
• Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

  1994cited by this paper
• Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus

  1993cited by this paper
• Broad recognition of cytotoxic T cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules.

  1992influential reference
• Down-regulation of homing receptors after T cell activation.

  1988cited by this paper
• A high proportion of T lymphocytes that infiltrate H-2-incompatible heart allografts in vivo express genes encoding cytotoxic cell-specific serine proteases, but do not express the MEL-14-defined lymph node homing receptor

  1988cited by this paper
• Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation.

  1987cited by this paper
• Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.

  1986cited by this paper
• Immunization against Viral Diseases

  1968cited by this paper
• IMMUNIZATION AGAINST VIRAL DISEASES.

  1965cited by this paper

• Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies.

  2024cites this paper
• Safety, Immunogenicity, and Efficacy of a Recombinant Vesicular Stomatitis Virus Vectored Vaccine Against Severe Fever with Thrombocytopenia Syndrome Virus and Heartland Bandavirus

  2024cites this paper
• Recombinant VSVs: A Promising Tool for Virotherapy

  2024cites this paper
• Rational selection of an ideal oncolytic virus to address current limitations in clinical translation.

  2023cites this paper
• Vesicular stomatitis virus-based vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein booster strategy

  2022cites this paper
• Current view on novel vaccine technologies to combat human infectious diseases

  2021cites this paper
• Oncolytic Virotherapy in Glioma Tumors

  2020cites this paper
• To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity

  2020cites this paper
• Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector

  2019cites this paper
• Baited vaccines: A strategy to mitigate rodent‐borne viral zoonoses in humans

  2018cites this paper
• Rhabdoviruses as vaccine platforms for infectious disease and cancer

  2018cites this paper
• Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy

  2018cites this paper
• Immunogenicity in African Green Monkeys of M Protein Mutant Vesicular Stomatitis Virus Vectors and Contribution of Vector-Encoded Flagellin

  2018cites this paper
• A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model

  2018cites this paper
• Ebola virus disease candidate vaccines under evaluation in clinical trials

  2016cites this paper
• Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

  2016cites this paper
• Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.

  2015cites this paper
• Lassa-Vesicular Stomatitis Chimeric Virus Safely Destroys Brain Tumors

  2015influential citation
• Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

  2015cites this paper
• RHABDOVIRUSES AS VACCINE VECTORS: FROM INITIAL DEVELOPMENT TO CLINICAL TRIALS

  2015cites this paper
• A respiratory vaccine for Ebola: close to a reality?

  2015cites this paper
• Type III Interferon Attenuates a Vesicular Stomatitis Virus-Based Vaccine Vector

  2014cites this paper
• A Novel, Live-Attenuated Vesicular Stomatitis Virus Vector Displaying Conformationally Intact, Functional HIV-1 Envelope Trimers That Elicits Potent Cellular and Humoral Responses in Mice

  2014cites this paper
• A Viable Recombinant Rhabdovirus Lacking Its Glycoprotein Gene and Expressing Influenza Virus Hemagglutinin and Neuraminidase Is a Potent Influenza Vaccine

  2014cites this paper
• Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors

  2013cites this paper
• mRNA Cap Methylation Influences Pathogenesis of Vesicular Stomatitis Virus In Vivo

  2013cites this paper
• Formulation and delivery of vaccines: Ongoing challenges for animal management

  2012cites this paper
• Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic Activity

  2012cites this paper
• Vesicular stomatitis virus with the rabies virus glycoprotein directs retrograde transsynaptic transport among neurons in vivo

  2012cites this paper
• The Immune Response to a Vesicular Stomatitis Virus Vaccine Vector Is Independent of Particulate Antigen Secretion and Protein Turnover Rate

  2012cites this paper
• Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

  2011cites this paper
• Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

  2011cites this paper
• Acute Pathogenesis of Recombinant Vesicular Stomatitis Virus Vaccine Vectors is Linked to Interleukin-1

  2011cites this paper
• Protection against Lethal Vaccinia Virus Challenge by Using an Attenuated Matrix Protein Mutant Vesicular Stomatitis Virus Vaccine Vector Expressing Poxvirus Antigens

  2010cites this paper
• Some Attenuated Variants of Vesicular Stomatitis Virus Show Enhanced Oncolytic Activity against Human Glioblastoma Cells relative to Normal Brain Cells

  2009cites this paper
• Viral strategies for studying the brain, including a replication‐restricted self‐amplifying delta‐G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi‐like expression

  2009cites this paper
• A recombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1).

  2009cites this paper
• Recombinant Vectors as Influenza Vaccines

  2009cites this paper
• Vesicular Stomatitis Virus Genomic RNA Persists In Vivo in the Absence of Viral Replication

  2009cites this paper
• Hybrid alphavirus–rhabdovirus propagating replicon particles are versatile and potent vaccine vectors

  2008cites this paper
• Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine

  2008cites this paper
• Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.

  2008cites this paper
• Single-Dose, Therapeutic Vaccination of Mice with Vesicular Stomatitis Virus Expressing Human Papillomavirus Type 16 E7 Protein

  2008cites this paper
• Desenvolvimento de estratégias vacinais contra tumores induzidos pelo vírus do papiloma humano tipo 16 (HPV-16) baseadas em linhagens geneticamente modificadas de Bacillus subtilis.

  2008cites this paper
• Use of viral vectors for the development of vaccines

  2007cites this paper
• Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits.

  2007cites this paper
• Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice

  2007cites this paper
• Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

  2007cites this paper
• Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus

  2007cites this paper
• Effects of the physico-chemical nature of two biomimetic crystals on the innate immune response.

  2007cites this paper
• Successful Topical Respiratory Tract Immunization of Primates

  2007cites this paper
• Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.

  2007cites this paper
• Rapid Pathogenesis Induced by a Vesicular Stomatitis Virus Matrix Protein Mutant: Viral Pathogenesis Is Linked to Induction of Tumor Necrosis Factor Alpha

  2006cites this paper
• Replication and Propagation of Attenuated Vesicular Stomatitis Virus Vectors In Vivo: Vector Spread Correlates with Induction of Immune Responses and Persistence of Genomic RNA

  2006cites this paper
• Nonsegmented Negative-Strand Viruses as Vaccine Vectors

  2006cites this paper
• Vesicular Stomatitis Virus

  2006cites this paper
• MINIREVIEW Nonsegmented Negative-Strand Viruses as Vaccine Vectors

  2006cites this paper
• Recombinant Vesicular Stomatitis Virus Vectors Expressing Herpes Simplex Virus Type 2 gD Elicit Robust CD4+ Th1 Immune Responses and Are Protective in Mouse and Guinea Pig Models of Vaginal Challenge

  2006cites this paper
• A Single-Cycle Vaccine Vector Based on Vesicular Stomatitis Virus Can Induce Immune Responses Comparable to Those Generated by a Replication-Competent Vector

  2005cites this paper
• A Vesicular Stomatitis Virus Recombinant Expressing Granulocyte-Macrophage Colony-Stimulating Factor Induces Enhanced T-Cell Responses and Is Highly Attenuated for Replication in Animals

  2005cites this paper
• Development and characterization of drug delivery systems for targeting mammalian cells and tissues: a review.

  2005cites this paper